Silencing HIV - Dr. Priti Kumar from the HOPE Collaboratory, DARE Collaboratory Community Advisory Board, September 20, 2022 Pathways Forward to End HIV: How HIV Cure Research is Helping to Advance HIV Vaccine Research - Dr. Shelly Karuna, Dr. Karine…
A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the clinicaltrials.gov online registry. Click the trial registry identifier numbers for a link to the full entry containing detailed information on the trial design, enrollment criteria, principal investigators and location(s).
Treatment Action Group (TAG) welcomes and celebrates the U.S. Food and Drug Administration’s (FDA) approval of Apretude brand cabotegravir, the first injectable medication for use as pre-exposure prophylaxis (PrEP) to reduce the risk of HIV transmission.
Yesterday, a widely reported presentation by Ricardo Diaz at the ongoing virtual International AIDS Conference (AIDS2020) disclosed that one out of 30 total participants in an HIV cure-related research trial conducted in Brazil has not experienced an HIV viral load rebound for a little over a year (64.7 weeks) after interrupting antiretroviral therapy (ART).
A resource listing of articles, reports, websites, and ongoing clinical trials related to the research effort to cure HIV infection.
The ACT NOW:END AIDS Coalition, of which TAG is a founding member, released this statement today calling for the administration’s efforts to end the HIV epidemic to be rooted in fact, science, and sensible policies that are consistent with the stated goal of ending HIV.
A resource listing of articles, reports, websites, and ongoing clinical trials related to HIV and aging.
Some individuals who initiate antiretroviral therapy (ART) experience limited recovery of CD4 T cell numbers despite suppression of HIV viral load to undetectable levels. The most common risk factors for this type of discordant response to ART are low CD4 T cell count at the time of starting and older age.
Treatment Action Group (TAG) welcomes the U.S. Department of Health and Human Services (HHS) pursuit of a lawsuit against Gilead Sciences, Inc., the manufacturer of Truvada and Descovy, the only two FDA-approved pills for pre-exposure prophlyaxis (PrEP) to prevent HIV.
On October 25, 2019, eight HIV/AIDS research, policy, and advocacy organizations filed an amicus brief in the U.S. District Court, in San Francisco, CA, in support of the plaintiffs in Staley v. Gilead.